Literature DB >> 22065087

Audit of acute Charcot's disease in the UK: the CDUK study.

F L Game1, R Catlow, G R Jones, M E Edmonds, E B Jude, G Rayman, W J Jeffcoate.   

Abstract

AIMS/HYPOTHESIS: We studied factors associated with the development and resolution of acute Charcot foot using a web-based observational study.
METHODS: Clinicians managing cases of acute Charcot foot in the UK and Ireland between June 2005 and February 2007 were invited to register anonymised details on a secure website.
RESULTS: A total of 288 cases (age 57.0 ± 11.3 years [mean ± SD]; 71.2% male) were registered from 76 centres. Of these, 36% of patients recalled an episode of relevant trauma in the preceding 6 months, while 12% had had surgery to the affected foot. In 101 (35%) cases, ulceration was present at registration and 20% of these had osteomyelitis. Non-removable off-loading devices were used at presentation in 35.4% of cases, with removable off-loading used in 50%. Data on resolution were available for 219 patients. The median time to resolution was 9 months in patients whose initial management included the use of non-removable off-loading, compared with 12 months in the remainder (p = 0.001). Bisphosphonates were administered intravenously in 25.4% and orally in 19.4% of cases. The median time to resolution in patients who received bisphosphonates was 12 months and was longer than in those who did not (10 months, p = 0.005). CONCLUSIONS/
INTERPRETATION: The median time to resolution was longer than in earlier series. Although limited by being observational and non-randomised, these data suggest that the use of non-removable off-loading at presentation may shorten the time to resolution. They provide no evidence to indicate that the use of bisphosphonates is beneficial.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22065087     DOI: 10.1007/s00125-011-2354-7

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  14 in total

Review 1.  The Charcot foot.

Authors:  W Jeffcoate; J Lima; L Nobrega
Journal:  Diabet Med       Date:  2000-04       Impact factor: 4.359

2.  Six-month treatment with alendronate in acute Charcot neuroarthropathy: a randomized controlled trial.

Authors:  Dario Pitocco; Valeria Ruotolo; Salvatore Caputo; Lorena Mancini; Chiara M Collina; Andrea Manto; Paolo Caradonna; Giovanni Ghirlanda
Journal:  Diabetes Care       Date:  2005-05       Impact factor: 19.112

Review 3.  The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes.

Authors:  William J Jeffcoate; Fran Game; Peter R Cavanagh
Journal:  Lancet       Date:  2005-08-10       Impact factor: 79.321

4.  Treatment of Eichenholtz stage I Charcot foot arthropathy with a weightbearing total contact cast.

Authors:  Michael S Pinzur; Tammy Lio; Matthew Posner
Journal:  Foot Ankle Int       Date:  2006-05       Impact factor: 2.827

5.  Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial.

Authors:  E B Jude; P L Selby; J Burgess; P Lilleystone; E B Mawer; S R Page; M Donohoe; A V Foster; M E Edmonds; A J Boulton
Journal:  Diabetologia       Date:  2001-11       Impact factor: 10.122

Review 6.  Charcot arthropathy of the diabetic foot. Current concepts and review of 36 cases.

Authors:  T K Pakarinen; H J Laine; S E Honkonen; J Peltonen; H Oksala; J Lahtela
Journal:  Scand J Surg       Date:  2002       Impact factor: 2.360

7.  Neuropathic arthropathy in the diabetic foot.

Authors:  R G Frykberg; G P Kozak
Journal:  Am Fam Physician       Date:  1978-05       Impact factor: 3.292

Review 8.  Charcot neuroarthropathy in diabetes mellitus.

Authors:  S M Rajbhandari; R C Jenkins; C Davies; S Tesfaye
Journal:  Diabetologia       Date:  2002-07-11       Impact factor: 10.122

9.  The effect of zoledronic acid on the clinical resolution of Charcot neuroarthropathy: a pilot randomized controlled trial.

Authors:  Toni-Karri Pakarinen; Heikki-Jussi Laine; Heikki Mäenpää; Pentti Mattila; Jorma Lahtela
Journal:  Diabetes Care       Date:  2011-05-18       Impact factor: 19.112

10.  Proinflammatory modulation of the surface and cytokine phenotype of monocytes in patients with acute Charcot foot.

Authors:  Luigi Uccioli; Anna Sinistro; Cristiana Almerighi; Chiara Ciaprini; Antonella Cavazza; Laura Giurato; Valeria Ruotolo; Francesca Spasaro; Erika Vainieri; Giovanni Rocchi; Alberto Bergamini
Journal:  Diabetes Care       Date:  2009-10-30       Impact factor: 19.112

View more
  21 in total

1.  Efficacy of medical treatment for Charcot neuroarthropathy: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Ashu Rastogi; Anil Bhansali; Edward B Jude
Journal:  Acta Diabetol       Date:  2021-01-13       Impact factor: 4.280

Review 2.  Treatment of acute Charcot foot with bisphosphonates: a systematic review of the literature.

Authors:  J-L Richard; M Almasri; S Schuldiner
Journal:  Diabetologia       Date:  2012-02-25       Impact factor: 10.122

3.  Diabetic charcot neuroarthropathy: prevalence, demographics and outcome in a regional referral centre.

Authors:  A O'Loughlin; E Kellegher; C McCusker; R Canavan
Journal:  Ir J Med Sci       Date:  2016-10-06       Impact factor: 1.568

4.  Who was first to diagnose and report neuropathic arthropathy of the foot and ankle: Jean-Martin Charcot or Herbert William Page?

Authors:  Lee J Sanders; Michael E Edmonds; William J Jeffcoate
Journal:  Diabetologia       Date:  2013-06-14       Impact factor: 10.122

5.  A literature-based guide to the conservative and surgical management of the acute Charcot foot and ankle.

Authors:  Valerie L Schade; Charles A Andersen
Journal:  Diabet Foot Ankle       Date:  2015-03-19

6.  Outcome after protected full weightbearing treatment in an orthopedic device in diabetic neuropathic arthropathy (Charcot arthropathy): a comparison of unilaterally and bilaterally affected patients.

Authors:  Niklas Renner; Stephan Hermann Wirth; Georg Osterhoff; Thomas Böni; Martin Berli
Journal:  BMC Musculoskelet Disord       Date:  2016-12-29       Impact factor: 2.362

7.  Duration of total contact casting for resolution of acute Charcot foot: a retrospective cohort study.

Authors:  Danielle A Griffiths; Michelle R Kaminski
Journal:  J Foot Ankle Res       Date:  2021-06-15       Impact factor: 2.303

8.  Etiology, pathophysiology and classifications of the diabetic Charcot foot.

Authors:  Nikolaos Papanas; Efstratios Maltezos
Journal:  Diabet Foot Ankle       Date:  2013-05-21

9.  Is Reconstruction of Unstable Midfoot Charcot Neuroarthropathy Cost Effective from a US Payer's Perspective?

Authors:  Rachel H Albright; Robert M Joseph; Dane K Wukich; David G Armstrong; Adam E Fleischer
Journal:  Clin Orthop Relat Res       Date:  2020-12       Impact factor: 4.755

10.  Developing an evidence-based clinical pathway for the assessment, diagnosis and management of acute Charcot Neuro-Arthropathy: a systematic review.

Authors:  Tamara E Milne; Joseph R Rogers; Ewan M Kinnear; Helen V Martin; Peter A Lazzarini; Thomas R Quinton; Frances M Boyle
Journal:  J Foot Ankle Res       Date:  2013-07-30       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.